MedPath

InterveXion Therapeutics LLC

InterveXion Therapeutics LLC logo
🇺🇸United States
Ownership
Private
Established
2004-01-01
Employees
51
Market Cap
-
Website
http://www.intervexion.com

Clinical Trials

5

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:3
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 2
2 (40.0%)

Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

Phase 2
Terminated
Conditions
Methamphetamine-dependence
Methamphetamine Abuse
Interventions
Other: Placebo
First Posted Date
2021-09-05
Last Posted Date
2024-10-04
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
61
Registration Number
NCT05034874
Locations
🇺🇸

Pillar Clinical Research, Richardson, Texas, United States

🇺🇸

Woodlands International Research Group, Little Rock, Arkansas, United States

🇺🇸

Artemis Institute for Clinical Research, San Diego, California, United States

and more 4 locations

Safety, Tolerability, and Pharmacokinetics of IXT-m200

Phase 1
Completed
Conditions
Healthy
Interventions
Other: Placebo
First Posted Date
2021-08-30
Last Posted Date
2023-06-01
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
9
Registration Number
NCT05027451
Locations
🇺🇸

Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

Phase 2
Terminated
Conditions
Methamphetamine Intoxication (Disorder)
Interventions
First Posted Date
2021-01-20
Last Posted Date
2023-11-18
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
20
Registration Number
NCT04715230
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

University of New Mexico Hospital, Albuquerque, New Mexico, United States

🇺🇸

Providence Regional Medical Center Everett, Everett, Washington, United States

and more 1 locations

Study of Antibody for Methamphetamine Outpatient Therapy

Phase 1
Completed
Conditions
Methamphetamine-dependence
Methamphetamine Abuse
Interventions
Drug: Placebo
First Posted Date
2017-11-08
Last Posted Date
2022-03-10
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
77
Registration Number
NCT03336866
Locations
🇺🇸

Anaheim Clinical Trials, Anaheim, California, United States

🇺🇸

PRA Health Sciences, Salt Lake City, Utah, United States

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Phase 1
Completed
Conditions
Methamphetamine Abuse
First Posted Date
2012-05-22
Last Posted Date
2014-05-13
Lead Sponsor
InterveXion Therapeutics, LLC
Target Recruit Count
42
Registration Number
NCT01603147
Locations
🇺🇸

Quintiles Phase 1 Services, Overland Park, Kansas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.